false 0000880242 0000880242 2024-01-22 2024-01-22
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 22, 2024
 
BioLargo, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
  
000-19709
  
65-0159115
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
 
 
14921 Chestnut St., Westminster, California
  
92683
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (888) 400-2863
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BLGO
OTCQB
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 7.01 Regulation FD Disclosure.
 
On January 22, 2024, BioLargo, Inc. published the press release which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading “Safe Harbor Act” in Exhibit 99.1 attached hereto.
 
 
Item 9.01. Financial Statements and Exhibits.
 
(d)      Exhibits.
 
 
Exhibit
No.
 Description
99.1 Press release
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Date: January 22, 2024
BIOLARGO, INC.
By:
 /s/ Dennis P. Calvert
Dennis P. Calvert
President and Chief Executive Officer
 
 

Exhibit 99.1

 

BioLargo Doubles Annual Revenues - Again

 

Westminster, CA – January 22, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its annual revenues for the year ended December 31, 2023, were more than double 2022 revenues, representing the second year in a row revenues have doubled.

 

BioLargo’s increase in sales were primarily driven by sales of Pooph, a blockbuster pet odor control product line that features safe, effective and eco-friendly products sold through national retailers like Amazon, Walmart, Chewy and more. BioLargo serves as a technology partner and supplier to Pooph, Inc., and they manage the national marketing, branding, and distribution for the Pooph line of products.

 

BioLargo President and CEO Dennis P. Calvert said, “The success of Pooph validates our business model of inventing a best-in-class technology-based product, proving it up through world-class R&D, and partnering to maximize commercial reach. The team at Pooph informs us that they expect to continue growing sales in 2024 and by doing so, they will continue to increase the value of its brand. These are both are great developments for BioLargo.”

 

He continued, “The response from the marketplace to our PFAS removal and water treatment related technologies as well as our long duration battery storage solution is highly encouraging for 2024 and beyond. We expect to earn our first revenues from our proprietary PFAS treatment technology this year thanks to our securing a key municipal drinking water project, the success of which we anticipate will springboard the technology into more and more projects as customers become more comfortable with our novel technology with superior claims over the competition.”

 

The company is still working to conclude its audit of its 2023 financial statements and intends to file its annual report with the SEC at the end of March. The revenue estimates for 2023 are preliminary and subject to change pending review and audit by the company’s independent registered public accounting firm.

 

About BioLargo, Inc.

 

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

 

Contact Information

 

Dennis P. Calvert

 

President and CEO, BioLargo, Inc.

 

888-400-2863

 

 
 

 

Safe Harbor Act

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

 
v3.23.4
Document And Entity Information
Jan. 22, 2024
Document Information [Line Items]  
Entity, Registrant Name BioLargo, Inc.
Document, Type 8-K
Document, Period End Date Jan. 22, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 000-19709
Entity, Tax Identification Number 65-0159115
Entity, Address, Address Line One 14921 Chestnut St.
Entity, Address, City or Town Westminster
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 92683
City Area Code 888
Local Phone Number 400-2863
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BLGO
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000880242
BioLargo (QX) (USOTC:BLGO)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more BioLargo (QX) Charts.
BioLargo (QX) (USOTC:BLGO)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more BioLargo (QX) Charts.